

# Friedreich's Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/F82A64FACFADEN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: F82A64FACFADEN

## Abstracts

The 7 major Friedreich's ataxia markets reached a value of US\$ 600.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,710.7 Million by 2034, exhibiting a growth rate (CAGR) of 9.98% during 2024-2034.

The Friedreich's ataxia market has been comprehensively analyzed in IMARC's new report titled "Friedreich's Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Genital warts refer to a sexually transmitted infection caused by a low-risk strain of human papillomavirus. The condition results in the formation of tiny bumps or growths in and around the genitals and rectum. Warts typically appear following one to eight months after exposure. The disease is transmitted through skin-to-skin contact and sexual activities, including vaginal, oral, and anal sex. The common indications associated with Friedreich's ataxia are mild bleeding, discomfort, burning sensation, itching, irritation, etc. This ailment often does not produce significant physical markers, but an outbreak might result in emotional problems like anxiety in some people. The diagnosis typically involves a review of the patient's medical history, underlying symptoms, and physical examination. The healthcare practitioner may also perform an acetowhite test, which helps to make Friedreich's ataxia more visible. Additionally, various diagnostic procedures, such as colposcopy and biopsy, are required to visually examine the cervix, vagina, and vulva in order to confirm a diagnosis.

The increasing prevalence of human papillomavirus infections caused by the non-usage of condoms or dental dams during sex is primarily driving the Friedreich's ataxia market. In addition to this, the rising incidence of several associated risk factors, such as a weakened immune system, multiple sexual partners, engaging in sexual activity at

an early age, etc., is also bolstering the market growth. Furthermore, the widespread utilization of topical immunomodulatory agents, including imiquimod and cidofovir, to stimulate the immune system in order to attack the virus that causes the warts is acting as another significant growth-inducing factor. Apart from this, the inflating application of cryosurgery, which utilizes liquid nitrogen to freeze and disrupt warts, is further creating a positive outlook for the market. Moreover, the emerging popularity of loop electrosurgical excision procedures for treating the condition is also propelling the market growth. This method uses a thin, low-voltage, electrically charged wire loop to separate warts from the skin by heating the margin of the affected area. Additionally, the escalating demand for interferon alfa-n3 injection to manage the ailment, since it can be administered directly into the lesion with a quicker onset of action, is expected to drive the Friedreich's ataxia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Friedreich's ataxia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Friedreich's ataxia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Friedreich's ataxia market in any manner.

#### Recent Developments:

In March 2024, Larimar Therapeutics, Inc. announced the dosing of the first patient in an open-label extension (OLE) trial assessing nomlabofusp subcutaneous injections at a dose of 25 mg per day for individuals with Friedreich's ataxia. Nomlabofusp (CTI-1601) is a new protein replacement therapy that targets the underlying cause of Friedreich's ataxia by delivering frataxin to the mitochondria.

In March 2024, Lexeo published preliminary findings from a subset of their second dose cohort of the SUNRISE-FA trial, demonstrating a rise in frataxin levels three months after treatment with LX2006 compared to pre-treatment baseline levels for people with Friedreich's ataxia cardiomyopathy.

In February 2024, Voyager Therapeutics, Inc. announced that the joint steering committee with Neurocrine Biosciences had chosen a lead development candidate for

Friedreich's ataxia program. The candidate combines a frataxin (FXN) gene replacement payload with an intravenous, blood-brain barrier penetrant, new capsid from Voyager's TRACER capsid discovery platform.

In February 2024, Biogen Inc. announced that the European Commission (EC) had approved SKYCLARYS (omaveloxolone) for the treatment of Friedreich's ataxia in adults and adolescents aged 16 and above. SKYCLARYS is the first medication approved in the European Union for this rare, genetically determined, progressive neurodegenerative disease.

#### Key Highlights:

Friedreich's ataxia affects one in every 50,000 people in the United States, with Western Europeans having the highest prevalence.

The worldwide prevalence of Friedreich's ataxia is 1 in 40,000.

Friedreich's ataxia is a disease that affects young people, as the development of symptoms usually begins before the age of 20.

Friedreich's ataxia is the most prevalent inherited ataxia in the Caucasian population.

The estimated incidence in Caucasians is around 1 in 29,000, with a carrier chance of 1 in 85.

Approximately 7% of patients with Friedreich's ataxia have diabetes.

#### Drugs:

Skyclarys (omaveloxolone) is FDA-approved medication in the United States for the treatment of Friedreich's ataxia in adults and adolescents aged 16 and above. The recommended dose is 150 mg to be administered orally once daily. Skyclarys is intended to stimulate nuclear factor erythroid 2-related factor 2 (NrF2), a transcription factor whose signaling is reduced in Friedreich's ataxia patients. NrF2 activates genes that improve mitochondrial function, increase antioxidant responses, and reduce inflammation.

Vatiquinone is a small molecule, first-in-class selective inhibitor of 15-Lipoxygenase (15-LO), an enzyme that regulates the energy and oxidative stress pathways that are disturbed in Friedreich's ataxia. Inhibiting 15-LO helps to reduce the effects of mitochondrial malfunction and oxidative stress, hence reducing ferroptosis and promoting neuronal survival.

Leriglitazone (MIN-102) is an orally bioavailable and selective PPAR $\gamma$  agonist with a potential best-in-class and first-in-class profile indicated for CNS diseases. It has demonstrated significant brain penetration and an acceptable safety profile. The medicine provided strong preclinical proof-of-concept in animal models of Friedreich's

ataxia by changing pathways that lead to neuroinflammation, demyelination, and mitochondrial failure.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Friedreich's ataxia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Friedreich's ataxia market

Reimbursement scenario in the market

In-market and pipeline drugs

### Competitive Landscape:

This report also provides a detailed analysis of the current Friedreich's ataxia marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results  
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:  
Market Insights

How has the Friedreich's ataxia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Friedreich's ataxia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Friedreich's ataxia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of Friedreich's ataxia across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of Friedreich's ataxia by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of Friedreich's ataxia by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with Friedreich's ataxia across the seven major markets?

What is the size of the Friedreich's ataxia patient pool (2018-2023) across the seven

major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Friedreich's ataxia?

What will be the growth rate of patients across the seven major markets?

## Friedreich's Ataxia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Friedreich's ataxia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Friedreich's ataxia market?

What are the key regulatory events related to the Friedreich's ataxia market?

What is the structure of clinical trial landscape by status related to the Friedreich's ataxia market?

What is the structure of clinical trial landscape by phase related to the Friedreich's ataxia market?

What is the structure of clinical trial landscape by route of administration related to the Friedreich's ataxia market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 FRIEDREICH'S ATAXIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
- 4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

### 5 FRIEDREICH'S ATAXIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 FRIEDREICH'S ATAXIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (?2018-2023?)
  - 7.2.2 Epidemiology Forecast (?2024-2034?)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (?2018-2023?)
  - 7.3.2 Epidemiology Forecast (?2024-2034?)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (?2018-2023?)
  - 7.4.2 Epidemiology Forecast (?2024-2034?)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (?2018-2023?)
  - 7.5.2 Epidemiology Forecast (?2024-2034?)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (?2018-2023?)
  - 7.6.2 Epidemiology Forecast (?2024-2034?)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (?2018-2023?)
  - 7.7.2 Epidemiology Forecast (?2024-2034?)
  - 7.7.3 Epidemiology by Age (?2018-2034?)



- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (?2018-2023?)
  - 7.8.2 Epidemiology Forecast (?2024-2034?)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (?2018-2023?)
  - 7.9.2 Epidemiology Forecast (?2024-2034?)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 FRIEDREICH'S ATAXIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 FRIEDREICH'S ATAXIA - UNMET NEEDS**

## **10 FRIEDREICH'S ATAXIA - KEY ENDPOINTS OF TREATMENT**

## **11 FRIEDREICH'S ATAXIA - MARKETED PRODUCTS**

- 11.1 List of Friedreich's Ataxia Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 FRIEDREICH'S ATAXIA - PIPELINE DRUGS**

### 12.1 List of Friedreich's Ataxia Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Omaveloxolone - Reata Pharmaceuticals

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

#### 12.1.2 Vatiquinone - PTC Therapeutics

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

#### 12.1.3 MIN-102 - Minoryx Therapeutics

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

#### 12.1.4 DT-216 - Design Therapeutics

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

#### 12.1.5 CTI-1601 - Larimar Therapeutics

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results
- 12.1.5.4 Safety and Efficacy
- 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. FRIEDREICH'S ATAXIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. FRIEDREICH'S ATAXIA – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 FRIEDREICH'S ATAXIA - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Friedreich's Ataxia - Market Size
    - 15.2.1.1 Market Size (?2018-2023?)
    - 15.2.1.2 Market Forecast (?2024-2034?)
  - 15.2.2 Friedreich's Ataxia - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (?2018-2023?)
    - 15.2.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.3 Market Scenario - United States
  - 15.3.1 Friedreich's Ataxia - Market Size
    - 15.3.1.1 Market Size (?2018-2023?)
    - 15.3.1.2 Market Forecast (?2024-2034?)
  - 15.3.2 Friedreich's Ataxia - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (?2018-2023?)
    - 15.3.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.3.3 Friedreich's Ataxia - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Friedreich's Ataxia - Market Size
    - 15.4.1.1 Market Size (?2018-2023?)
    - 15.4.1.2 Market Forecast (?2024-2034?)
  - 15.4.2 Friedreich's Ataxia - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (?2018-2023?)
    - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.4.3 Friedreich's Ataxia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Friedreich's Ataxia - Market Size
    - 15.5.1.1 Market Size (?2018-2023?)
    - 15.5.1.2 Market Forecast (?2024-2034?)
  - 15.5.2 Friedreich's Ataxia - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (?2018-2023?)

- 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.5.3 Friedreich's Ataxia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Friedreich's Ataxia - Market Size
    - 15.6.1.1 Market Size (?2018-2023?)
    - 15.6.1.2 Market Forecast (?2024-2034?)
  - 15.6.2 Friedreich's Ataxia - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (?2018-2023?)
    - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.6.3 Friedreich's Ataxia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Friedreich's Ataxia - Market Size
    - 15.7.1.1 Market Size (?2018-2023?)
    - 15.7.1.2 Market Forecast (?2024-2034?)
  - 15.7.2 Friedreich's Ataxia - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (?2018-2023?)
    - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.7.3 Friedreich's Ataxia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Friedreich's Ataxia - Market Size
    - 15.8.1.1 Market Size (?2018-2023?)
    - 15.8.1.2 Market Forecast (?2024-2034?)
  - 15.8.2 Friedreich's Ataxia - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (?2018-2023?)
    - 15.8.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.8.3 Friedreich's Ataxia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Friedreich's Ataxia - Market Size
    - 15.9.1.1 Market Size (?2018-2023?)
    - 15.9.1.2 Market Forecast (?2024-2034?)
  - 15.9.2 Friedreich's Ataxia - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (?2018-2023?)
    - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.9.3 Friedreich's Ataxia - Access and Reimbursement Overview

## **16 FRIEDREICH'S ATAXIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 FRIEDREICH'S ATAXIA MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 FRIEDREICH'S ATAXIA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Friedreich's Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/F82A64FACFADEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F82A64FACFADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

